Novosanis launches Colli-Pee® containing UAS Large Volumes, offering a new solution for oncology research
You are here
Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UASTM, for the preservation of extracellular vesicle (EV) RNA, and cell-free DNA (cfDNA) in urine, collected with Colli-Pee®. Novosanis hereby offers a solution for applications in the field of oncology research and possibly beyond.
Colli-Pee® containing UASTM allows for standardized and volumetric collection of urine. The device architecture enables immediate mixing of urine with the new UASTM preservative as well as preventing microbial growth and physiochemical changes.
Yellow is the new red | Urine for oncology research
The use of non-invasive liquid biopsies for cancer research has gained interest over the past years. Several studies have shown the potential of urine as a sample type.
Urine sampling offers several benefits:
- Easily accessible and available in larger quantities (approx. 40 mL)
- Non-invasive
- Applicable for home collection
- Cost efficient
- Not limited by the health status of a patient
- Does not entail any risk of transmission of blood-borne pathogens
UASTM | Preservative designed for oncology research
First-void urine collected with Colli-Pee® containing UASTM has been shown to prevent degradation of EV-RNA and cfDNA.
UASTM offers the following characteristics:
- Non-lytic
- Prevents microbial growth for at least 14 days when stored at room temperature
- Preservative to sample ratio 2:5 for optimal preservation performance across a wide spectrum of urinary samples and applications
Next to technical assessment, UASTM has been evaluated on urine samples from the URODETECT project, which uses urine as a non-invasive liquid biopsy for prostate and breast cancer biomarker detection. First studies have already shown extraction compatibility for cfDNA filtration, centrifugation and precipitation. Additional research projects are ongoing on characterization of EVs and patient cohort performance testing. Importantly, upon immediate mixing of urine with UASTM, urine samples have shown stability of cfDNA and EV-RNA for at least 7 days at room temperature.
"Development of a urine preservative, that can maintain the composition and integrity of a urine sample opens new avenues for cancer biomarker research" says Koen Beyers, CTO at Novosanis. “A big thank you to the teams at both Novosanis in Belgium and DNA Genotek in Canada. We’re all really excited about this RUO launch.”